

Diarrhea and Pneumonia Working Group Lead Partner – Terms of Reference

Overview

The Diarrhea and Pneumonia Working Group aims to accelerate treatment scale-up across 10 high-burden countries. In 2012, the Working Group supported governments and key stakeholders to develop costed [national scale-up plans](#) for child essential medicines and key fundraising and implementation progress has already been made to date across all countries. Lead partners for each country are responsible for supporting resource mobilization, partner coordination and initial implementation efforts:

Country	Organization	Name
Bangladesh	icddr,b	Dr. Shams El Airfeen, shams@icddr.org
Democratic Republic of Congo	MSH	Dr. Narcisse Embeke, nembeke@msh.org
Ethiopia	PATH	Dwan Dixon, ddixon@path.org
India	CHAI	Ravi Bhatnagar, rbhatnagar@clintonhealthaccess.org
Kenya	CHAI	Rosemary Kihoto, rkihoto@clintonhealthaccess.org
Niger	UNICEF	Dr. Toure Hamadassalia, htoure@unicef.org
Nigeria	CHAI TSHIP	Jason Houdek, jhoudek@clintonhealthaccess.org Dr. Francis Ohanyido fohanyido@tshipnigeria.org
Pakistan	Save the Children	Dr. Qudsia Uzma, qudsia.uzma@savethechildren.org
Tanzania	PSI	Brendd Mshiu, bmsheu@psi.or.tz
Uganda	CHAI	Damien Kirchhoffer, dkirchhoffer@clintonhealthaccess.org

Lead partners were selected based on the following qualifications:

- Strong relationship with MOH/government at program and leadership levels
- Neutral broker to coordinate efforts across partners, including identifying and engaging partners from both public and private sectors that are best positioned to support implementation
- Willingness/capacity to drive strategy development and implementation in public and private sectors
- Goal of reducing deaths from childhood pneumonia and diarrhea fits in with overall organization mission and is an active program area in current program plans
- Willingness and capacity to support diarrhea and pneumonia scale up efforts over next several years independent of any short-term financial support to jumpstart implementation

Lead partner progress on implementation activities will be tracked regularly and reviewed during quarterly meetings. The Working Group will share new tools and guidance developed by Subgroups to facilitate country efforts as well as relevant updates on global initiatives and new funding opportunities Lead Partners .

Responsibilities

- Refine budget for national scale-up plan for diarrhea and pneumonia treatment to clarify total estimated need, total contributions (government and partner), and gap
- Work with MOH and partners (in context of health sector coordination mechanism) to ensure key activities in strategy are included in health sector priorities and health sector budget
- Support the government to improve partner coordination and ensure harmonized approach and joint work planning toward implementation of national scale up plan for diarrhea and pneumonia treatment
- Support government to host regular stakeholder meetings
- Actively fundraise or support resource mobilization efforts for implementation of the national scale-up plan, including advocacy with local bilateral missions and identifying partner support to fill gaps
- Maintain mapping of key partners involved in in-country implementation
- Coordinate with UN Commission and GAPPD country planning and process
- Pursue OTC status for zinc and favorable policy change for amoxicillin, if needed
- Share regular updates on progress with global Diarrhea and Pneumonia Working Group

Key milestones for 2013

- National scale-up plan endorsed by government (or scale-up interventions integrated into broader RMNCH strategy, as appropriate) and budget refined
- Favorable policy changes secured for zinc and amoxicillin
- Government-led coordinating mechanism established and partner mapping completed
- Proposals outlining local market shaping interventions developed
- Demand and supply side strategies developed
- Country updates completed each quarter and participation in at least 1 quarterly Working Group meeting

Key milestones for 2014¹

- Regular meetings of government-led coordinating mechanism for diarrhea and pneumonia and key outputs, priorities, and issues raised during meetings shared with Working Group
- Support provided to governments in preparing robust proposals for new funding opportunities (e.g. iCCM co-financing, RMNCH Trust Fund, others)
- Favorable policy changes for amoxicillin—specifically, appropriate antibiotic included in national EML and policy allowing local community-based providers to dispense recommended antibiotic
- At least 1 recommended antibiotic registered in country
- Baseline data and updates for key indicators collected (with support from the M&E Subgroup as needed)
- Country updates completed each quarter and participation in at least 1 quarterly Working Group meeting

¹ For Lead Partners who have NOT yet achieved 2013 milestones, follow-up discussions will be arranged to discuss timelines for completion and potential additional TA from the Working Group for countries, as needed